💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Enalapril Maleate

CHEMBL1200659 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
492.5 g/mol
LogP
—
Phase
4

The maleate salt form of enalapril, this blood pressure medication relaxes blood vessels by blocking the enzyme that produces the vessel-constricting hormone angiotensin II. The maleate salt form is the standard oral formulation.

الوزن الجزيئي

492,5000 g/mol

TPSA

171,00 Ų

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Melanoma Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Hyperlipidemia Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

آلية العمل

Prodrug converted to enalaprilat; inhibits ACE preventing angiotensin I to II conversion.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Prodrug converted to enalaprilat; inhibits ACE preventing angiotensin I to II conversion.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C20H28N2O5.C4H4O4/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25;5-3(6)1-2-4(7)8/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,16-,17-;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H32N2O9

                    

                    
                    

                        
HBD / HBA

                        
4 / 10

                    

                    
                    

                        
الروابط القابلة للدوران

                        
12

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
The maleate salt form of enalapril, this blood pressure medication relaxes blood vessels by blocking the enzyme that produces the vessel-constricting hormone angiotensin II. The maleate salt form is the standard oral formulation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Prodrug converted to enalaprilat; inhibits ACE preventing angiotensin I to II conversion.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Enalapril Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200659.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5388961.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.